A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Inclusion Criteria:

1. Subject was enrolled in Protocol No. CP-106 and successfully completed 12 treatment
cycles.

2. Subject must have been classified as a responder at the time of completion of
Protocol No. CP-106 [i.e., SD or better per RECIST Committee criteria or stable
symptoms or better (defined as an average daily frequency of bowel movements,
flushing episodes and/or wheezing episodes that is the same as or less than the
average daily frequency of bowel movements, flushing episodes and/or wheezing
episodes recorded during the 14-day screening period prior to enrollment in Protocol
No. CP-106)].

3. Subject must understand and voluntarily sign the informed consent document.

4. Subject must have adequate organ function defined as follows: Absolute granulocyte
count (AGC) >1,500/mm3, hemoglobin >8 g/dl, platelets >100,000/mm3, serum bilirubin
<1.5 x upper limit of normal (ULN), serum creatinine <1.5 mg/dL, SGOT ≤Grade 1 per
NCI CTCAE, SGPT ≤Grade 1 per NCI CTCAE.

5. Women of child bearing potential (WCBP) must have a negative serum or urine pregnancy
test. In addition sexually active WCBP must agree to use adequate contraceptive
methods (oral, injectable or implantable hormonal contraceptive; tubal ligation;
intra-uterine devices; barrier contraceptive with spermicide; or vasectomized
partner).

Exclusion Criteria:

1. Subject who was enrolled in Protocol No. CP-106 and who did not successfully complete
12 treatment cycles.

2. If WCBP, pregnant, lactating or not using adequate contraception.

3. Clinically relevant active infection or serious co-morbid medical conditions that are
uncontrolled or whose control may be jeopardized by atiprimod treatment.

4. Psychiatric disorders rendering subjects incapable of complying with the requirements
of the protocol.

5. Any condition which, in the opinion of the Investigator, places the subject at
unacceptable risk if he/she were to participate in the study.

6. As atiprimod is a potent inhibitor of CYP2D6, the use of drugs that are substrates of
CYP2D6 (e.g. beta blockers, antidepressants, and antipsychotic;) will not be allowed
while on study.